In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``SSI Reform Act of 1993''.

SEC. 2. INCREASE IN INCOME AND RESOURCE ELIGIBILITY STANDARDS AND 
              BENEFITS; ELIMINATION OF CERTAIN RESOURCE EXCLUSIONS.

    (a) Increase in Income and Resource Eligibility Standards.--
            (1) In general.--Section 1611 of the Social Security Act 
        (42 U.S.C. 1382) is amended--
                    (A) in subsection (a)--
                            (i) in paragraph (1)(A)--
                                    (I) by striking ``$1,752'' and 
                                inserting ``the adjusted poverty 
                                line''; and
                                    (II) by striking ``1974'' and 
                                inserting ``1994'';
                            (ii) in paragraph (2)(A)--
                                    (I) by striking ``$2,628'' and 
                                inserting ``150 percent of the adjusted 
                                poverty line''; and
                                    (II) by striking ``1974'' and 
                                inserting ``1994''; and
                            (iii) in paragraph (3)--
                                    (I) in subparagraph (A), by 
                                striking ``and to $3,000 on January 1, 
                                1989'' and inserting ``to $3,000 on 
                                January 1, 1989, and to $10,500 on 
                                January 1, 1994''; and
                                    (II) in subparagraph (B), by 
                                striking ``and to $3,000 on January 1, 
                                1989'' and inserting ``to $3,000 on 
                                January 1, 1989, and to $7,000 on 
                                January 1, 1994''; and
                    (B) in subsection (b)--
                            (i) in paragraph (1)--
                                    (I) by striking ``$1,752'' and 
                                inserting ``the adjusted poverty 
                                line''; and
                                    (II) by striking ``1974'' and 
                                inserting ``1994''; and
                            (ii) in paragraph (2)--
                                    (I) by striking ``$2,628'' and 
                                inserting ``150 percent of the adjusted 
                                poverty line''; and
                                    (II) by striking ``1974'' and 
                                inserting ``1994''.
            (2) Adjusted poverty line.--Subsection (a) of such section 
        (42 U.S.C. 1382(a)) is amended by adding at the end the 
        following:
    ``(4)(A) For purposes of this subsection and subsection (b), the 
term `adjusted poverty line' means, with respect to a family--
            ``(i) 80 percent of the poverty line for calendar year 
        1994;
            ``(ii) 90 percent of the poverty line for calendar year 
        1995;
            ``(iii) 100 percent of the poverty line for calendar year 
        1996;
            ``(iv) 110 percent of the poverty line for calendar year 
        1997; and
            ``(v) 120 percent of the poverty line for calendar year 
        1998 and each calendar year thereafter.
    ``(B) As used in subparagraph (A), the term `poverty line' means, 
with respect to a family, the official poverty line (as defined by the 
Office of Management and Budget, and revised annually in accordance 
with section 673(2) of the Omnibus Budget Reconciliation Act of 1981) 
applicable to a family of the size involved.''.
            (3) No reduction in benefits.--The amendments made by this 
        subsection shall not apply to any individual or couple whose 
        supplemental security income benefits under title XVI of the 
        Social Security Act would be reduced by reason of such 
        application.
    (b) Elimination of Certain Resource Exclusions.--Section 1613 of 
such Act (42 U.S.C. 1382b) is amended--
            (1) in the 1st sentence of subsection (a)--
                    (A) in paragraph (2)--
                            (i) by striking ``(A)''; and
                            (ii) by striking subparagraph (B);
                    (B) in paragraph (4), by adding ``and'' at the end;
                    (C) by striking all that follows paragraph (6);
                    (D) in paragraph (6), by striking the semicolon and 
                inserting a period; and
                    (E) by striking paragraph (5) and redesignating 
                paragraph (6) as paragraph (5); and
            (2) by striking subsection (d).

SEC. 3. IN-KIND SUPPORT AND MAINTENANCE DISREGARDED IN DETERMINING 
              INCOME.

    Section 1612(a)(2) of the Social Security Act (42 U.S.C. 
1382a(a)(2)) is amended--
            (1) by inserting ``(other than support or maintenance 
        furnished in kind)'' after ``all other income'';
            (2) in subparagraph (A)--
                    (A) by striking ``or kind'';
                    (B) by striking clause (i) and redesignating 
                clauses (ii) and (iii) as clauses (i) and (ii), 
                respectively; and
                    (C) in clause (ii) (as so redesignated), by 
                striking ``and the provisions of clause (i) shall not 
                be applicable''.

SEC. 4. WORK INCENTIVE.

    Section 1612(b)(4) of the Social Security Act (42 U.S.C. 
1382a(b)(4)) is amended--
            (1) by striking ``$780'' each place such term appears and 
        inserting ``$2,400''; and
            (2) by striking ``one-half'' each place such term appears 
        and inserting ``\2/3\''.

SEC. 5. PHASED-IN EXPANSION OF ELIGIBILITY BY REASON OF AGE.

    (a) Age 64 for Calendar Year 1994.--
            (1) In general.--Section 1614(a)(1)(A) of the Social 
        Security Act (42 U.S.C. 1382c(a)(1)(A)) is amended by striking 
        ``65'' and inserting ``64''.
            (2) Conforming amendments.--
                    (A) Section 1615(a)(1) of such Act (42 U.S.C. 
                1382d(a)(1)) is amended by striking ``65'' and 
                inserting ``64''.
                    (B) Section 1612(b)(4) of such Act (42 U.S.C. 
                1382a(b)) is amended by striking ``65'' each place such 
                term appears and inserting ``64''.
            (3) Effective date.--The amendments made by this subsection 
        shall take effect on January 1, 1994.
    (b) Age 63 for Calendar Year 1995.--
            (1) In general.--Section 1614(a)(1)(A) of such Act (42 
        U.S.C. 1382c(a)(1)(A)), as amended by subsection (a)(1) of this 
        section, is amended by striking ``64'' and inserting ``63''.
            (2) Conforming amendments.--
                    (A) Section 1615(a)(1) of such Act (42 U.S.C. 
                1382d(a)(1)), as amended by subsection (a)(2)(A) of 
                this section, is amended by striking ``64'' and 
                inserting ``63''.
                    (B) Section 1612(b)(4) of such Act (42 U.S.C. 
                1382a(b)), as amended by subsection (a)(2)(B) of this 
                section, is amended by striking ``64'' each place such 
                term appears and inserting ``63''.
            (3) Effective date.--The amendments made by this subsection 
        shall take effect on January 1, 1995.
    (c) Age 62 Thereafter.--
            (1) In general.--Section 1614(a)(1)(A) of such Act (42 
        U.S.C. 1382c(a)(1)(A)), as amended by paragraph (2)(A) of this 
        subsection, is amended by striking ``63'' and inserting ``62''.
            (2) Conforming amendments.--
                    (A) Section 1615(a)(1) of such Act (42 U.S.C. 
                1382d(a)(1)), as amended by subsections (a)(2)(A) and 
                (b)(2)(A) of this section, is amended by striking 
                ``63'' and inserting ``62''.
                    (B) Section 1612(b)(4) of such Act (42 U.S.C. 
                1382a(b)), as amended by subsections (a)(2)(B) and 
                (b)(2)(B) of this section, is amended by striking 
                ``63'' each place such term appears and inserting 
                ``62''.
            (3) Effective date.--The amendments made by this subsection 
        shall take effect on January 1, 1996.
Example Output: SSI Reform Act of 1993 - Amends title XVI (Supplemental Security Income) (SSI) of the Social Security Act to:  (1) increase the limit on the amount of income and resources needed to qualify for SSI; (2) increase the amount of SSI benefits payable; (3) eliminate certain resource exclusions and increase certain earned income exclusions; (4) disregard in-kind support and maintenance in determining income; and (5) phase-in an expansion of eligibility based on age.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Public Safety Officer Medal of Valor 
Act of 2001''.

SEC. 2. AUTHORIZATION OF MEDAL.

    After September 1, 2001, the President may award, and present in 
the name of Congress, a Medal of Valor of appropriate design, with 
ribbons and appurtenances, to a public safety officer who is cited by 
the Attorney General, upon the recommendation of the Medal of Valor 
Review Board, for extraordinary valor above and beyond the call of 
duty. The Public Safety Medal of Valor shall be the highest national 
award for valor by a public safety officer.

SEC. 3. MEDAL OF VALOR BOARD.

    (a) Establishment of Board.--There is established a Medal of Valor 
Review Board (hereinafter in this Act referred to as the ``Board''), 
which shall be composed of 11 members appointed in accordance with 
subsection (b) and shall conduct its business in accordance with this 
Act.
    (b) Membership.--
            (1) Members.--The members of the Board shall be individuals 
        with knowledge or expertise, whether by experience or training, 
        in the field of public safety, of which--
                    (A) two shall be appointed by the majority leader 
                of the Senate;
                    (B) two shall be appointed by the minority leader 
                of the Senate;
                    (C) two shall be appointed by the Speaker of the 
                House of Representatives;
                    (D) two shall be appointed by the minority leader 
                of the House of Representatives; and
                    (E) three shall be appointed by the President, 
                including one with experience in firefighting, one with 
                experience in law enforcement, and one with experience 
                in emergency services.
            (2) Term.--The term of a Board member shall be 4 years.
            (3) Vacancies.--Any vacancy in the membership of the Board 
        shall not affect the powers of the Board and shall be filled in 
        the same manner as the original appointment.
            (4) Operation of the board.--
                    (A) Chairman.--The Chairman of the Board shall be 
                elected by the members of the Board from among the 
                members of the Board.
                    (B) Meetings.--The Board shall conduct its first 
                meeting not later than 90 days after the appointment of 
                the last member appointed of the initial group of 
                members appointed to the Board. Thereafter, the Board 
                shall meet at the call of the Chairman of the Board. 
                The Board shall meet not less often than twice each 
                year.
                    (C) Voting and rules.--A majority of the members 
                shall constitute a quorum to conduct business, but the 
                Board may establish a lesser quorum for conducting 
                hearings scheduled by the Board. The Board may 
                establish by majority vote any other rules for the 
                conduct of the Board's business, if such rules are not 
                inconsistent with this Act or other applicable law.
    (c) Duties.--The Board shall select candidates as recipients of the 
Medal of Valor from among those applications received by the National 
Medal of Valor Office. Not more often than once each year, the Board 
shall present to the Attorney General the name or names of those it 
recommends as Medal of Valor recipients. In a given year, the Board 
shall not be required to select any recipients but may not select more 
than 5 recipients. The Attorney General may in extraordinary cases 
increase the number of recipients in a given year. The Board shall set 
an annual timetable for fulfilling its duties under this Act.
    (d) Hearings.--
            (1) In general.--The Board may hold such hearings, sit and 
        act at such times and places, administer such oaths, take such 
        testimony, and receive such evidence as the Board considers 
        advisable to carry out its duties.
            (2) Witness expenses.--Witnesses requested to appear before 
        the Board may be paid the same fees as are paid to witnesses 
        under section 1821 of title 28, United States Code. The per 
        diem and mileage allowances for witnesses shall be paid from 
        funds appropriated to the Board.
    (e) Information From Federal Agencies.--The Board may secure 
directly from any Federal department or agency such information as the 
Board considers necessary to carry out its duties. Upon the request of 
the Board, the head of such department or agency may furnish such 
information to the Board.
    (f) Information To Be Kept Confidential.--The Board shall not 
disclose any information which may compromise an ongoing law 
enforcement investigation or is otherwise required by law to be kept 
confidential.

SEC. 4. BOARD PERSONNEL MATTERS.

    (a) Compensation of Members.--(1) Except as provided in paragraph 
(2), each member of the Board shall be compensated at a rate equal to 
the daily equivalent of the annual rate of basic pay prescribed for 
level IV of the Executive Schedule under section 5315 of title 5, 
United States Code, for each day (including travel time) during which 
such member is engaged in the performance of the duties of the Board.
    (2) All members of the Board who serve as officers or employees of 
the United States, a State, or a local government, shall serve without 
compensation in addition to that received for those services.
    (b) Travel Expenses.--The members of the Board shall be allowed 
travel expenses, including per diem in lieu of subsistence, at rates 
authorized for employees of agencies under subchapter I of chapter 57 
of title 5, United States Code, while away from their homes or regular 
places of business in the performance of service for the Board.

SEC. 5. DEFINITIONS.

    In this Act:
            (1) Public safety officer.--The term ``public safety 
        officer'' means a person serving a public agency, with or 
        without compensation, as a firefighter, law enforcement 
        officer, or emergency services officer, as determined by the 
        Attorney General. For the purposes of this paragraph, the term 
        ``law enforcement officer'' includes a person who is a 
        corrections or court officer or a civil defense officer.
            (2) State.--The term ``State'' means each of the several 
        States of the United States, the District of Columbia, the 
        Commonwealth of Puerto Rico, the Virgin Islands, Guam, American 
        Samoa, and the Commonwealth of the Northern Mariana Islands.

SEC. 6. AUTHORIZATION OF APPROPRIATIONS.

    There are authorized to be appropriated to the Attorney General 
such sums as may be necessary to carry out this Act.

SEC. 7. NATIONAL MEDAL OF VALOR OFFICE.

    There is established within the Department of Justice a National 
Medal of Valor Office. The Office shall provide staff support to the 
Board to establish criteria and procedures for the submission of 
recommendations of nominees for the Medal of Valor and for the final 
design of the Medal of Valor.

SEC. 8. CONFORMING REPEAL.

    Section 15 of the Federal Fire Prevention and Control Act of 1974 
(15 U.S.C. 2214) is amended--
            (1) by striking subsection (a) and inserting the following 
        new subsection (a):
    ``(a) Establishment.--There is hereby established an honorary award 
for the recognition of outstanding and distinguished service by public 
safety officers to be known as the Director's Award For Distinguished 
Public Safety Service (`Director's Award').'';
            (2) in subsection (b)--
                    (A) by striking paragraph (1); and
                    (B) by striking ``(2)'';
            (3) by striking subsections (c) and (d) and redesignating 
        subsections (e), (f), and (g) as subsections (c), (d), and (e), 
        respectively; and
            (4) in subsection (c), as so redesignated--
                    (A) by striking paragraph (1); and
                    (B) by striking ``(2)''.

SEC. 9. CONSULTATION REQUIREMENT.

    The Board shall consult with the Institute of Heraldry within the 
Department of Defense regarding the design and artistry of the Medal of 
Valor. The Board may also consider suggestions received by the 
Department of Justice regarding the design of the medal, including 
those made by persons not employed by the Department.

            Passed the Senate May 14, 2001.

            Attest:

                                                             Secretary.
107th CONGRESS

  1st Session

                                 S. 39

_______________________________________________________________________

                                 AN ACT

  To provide a national medal for public safety officers who act with 
 extraordinary valor above and beyond the call of duty, and for other 
                               purposes.
Example Output: Public Safety Officer Medal of Valor Act of 2001 - Allows the President to award, and present in the name of the Congress, a Medal of Valor to a public safety officer cited by the Attorney General, upon the recommendation of the Medal of Valor Review Board, for extraordinary valor above and beyond the call of duty. Provides that the Public Safety Medal of Valor shall be the highest national award for valor by a public safety officer.Establishes a Medal of Valor Review Board to select candidates to receive the Medal from among applications received by the National Medal of Valor Office. Requires the Board to consult with the Institute of Heraldry in the Department of Defense regarding the design of the Medal.Authorizes appropriations.Establishes within the Department of Justice a National Medal of Valor Office to provide staff support to the Board to establish criteria and procedures for the submission of nominee recommendations for the Medal and for the final design of the Medal.Amends the Fire Prevention and Control Act of 1974 to establish an honorary Director's (Director of the Federal Emergency Management Agency) Award for Distinguished Public Safety Service for the recognition of outstanding and distinguished service by public safety officers (repeals provisions regarding the President's Award for Outstanding Public Safety Service and the Secretary of Commerce's Award for Distinguished Public Safety Service).

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Preserve Access to Affordable 
Generics Act''.

SEC. 2. CONGRESSIONAL FINDINGS AND DECLARATION OF PURPOSES.

    (a) Findings.--The Congress finds that--
            (1) prescription drugs make up 11 percent of the national 
        health care spending but are 1 of the largest and fastest 
        growing health care expenditures;
            (2) 56 percent of all prescriptions dispensed in the United 
        States are generic drugs, yet they account for only 13percent 
        of all expenditures;
            (3) generic drugs, on average, cost 63 percent less than 
        their brand-name counterparts;
            (4) consumers and the health care system would benefit from 
        free and open competition in the pharmaceutical market and the 
        removal of obstacles to the introduction of generic drugs;
            (5) full and free competition in the pharmaceutical 
        industry, and the full enforcement of antitrust law to prevent 
        anticompetitive practices in this industry, will lead to lower 
        prices, greater innovation, and inure to the general benefit of 
        consumers.
            (6) the Federal Trade Commission has determined that some 
        brand name pharmaceutical manufacturers collude with generic 
        drug manufacturers to delay the marketing of competing, low-
        cost, generic drugs;
            (7) collusion by the brand name pharmaceutical 
        manufacturers is contrary to free competition, to the interests 
        of consumers, and to the principles underlying antitrust law;
            (8) in 2005, 2 appellate court decisions reversed the 
        Federal Trade Commission's long-standing position, and upheld 
        settlements that include pay-offs by brand name pharmaceutical 
        manufacturers to generic manufacturers designed to keep generic 
        competition off the market;
            (9) in the 6 months following the March 2005 court 
        decisions, the Federal Trade Commission found there were three 
        settlement agreements in which the generic received 
        compensation and agreed to a restriction on its ability to 
        market the product;
            (10) the FTC found that more than \2/3\ of the 
        approximately ten settlement agreements made in 2006 include a 
        pay-off from the brand in exchange for a promise by the generic 
        company to delay entry into the market; and
            (11) settlements which include a payment from a brand name 
        manufacturer to a generic manufacturer to delay entry by 
        generic drugs are anti-competitive and contrary to the 
        interests of consumers.
    (b) Purposes.--The purposes of this Act are--
            (1) to enhance competition in the pharmaceutical market by 
        prohibiting anticompetitive agreements and collusion between 
        brand name and generic drug manufacturers intended to keep 
        generic drugs off the market;
            (2) to support the purpose and intent of antitrust law by 
        prohibiting anticompetitive agreements and collusion in the 
        pharmaceutical industry; and
            (3) to clarify the law to prohibit payments from brand name 
        to generic drug manufacturers with the purpose to prevent or 
        delay the entry of competition from generic drugs.

SEC. 3. UNLAWFUL COMPENSATION FOR DELAY.

    The Clayton Act (15 U.S.C. 12 et seq.) is amended--
            (1) by redesignating section 25 as section 29; and
            (2) by inserting after section 27 the following:

``SEC. 28. UNLAWFUL INTERFERENCE WITH GENERIC MARKETING.

    ``(a) It shall be unlawful under this Act for any person, in 
connection with the sale of a drug product, to directly or indirectly 
be a party to any agreement resolving or settling a patent infringement 
claim which--
            ``(1) an ANDA filer receives anything of value; and
            ``(2) the ANDA filer agrees not to research, develop, 
        manufacture, market, or sell the ANDA product for any period of 
        time.
    ``(b) Nothing in this section shall prohibit a resolution or 
settlement of patent infringement claim in which the value paid by the 
NDA holder to the ANDA filer as a part of the resolution or settlement 
of the patent infringement claim includes no more than the right to 
market the ANDA product prior to the expiration of the patent that is 
the basis for the patent infringement claim.
    ``(c) In this section:
            ``(1) The term `agreement' means anything that would 
        constitute an agreement under section 1 of the Sherman Act (15 
        U.S.C. 1) or section 5 of the Federal Trade Commission Act (15 
        U.S.C. 45).
            ``(2) The term `agreement resolving or settling a patent 
        infringement claim' includes, any agreement that is contingent 
        upon, provides a contingent condition for, or is otherwise 
        related to the resolution or settlement of the claim.
            ``(3) The term `ANDA' means an abbreviated new drug 
        application, as defined under section 505(j) of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)).
            ``(4) The term `ANDA filer' means a party who has filed an 
        ANDA with the Federal Drug Administration.
            ``(5) The term `ANDA product' means the product to be 
        manufactured under the ANDA that is the subject of the patent 
        infringement claim.
            ``(6) The term `drug product' means a finished dosage form 
        (e.g., tablet, capsule, or solution) that contains a drug 
        substance, generally, but not necessarily, in association with 
        1 or more other ingredients, as defined in section 314.3(b) of 
        title 21, Code of Federal Regulations.
            ``(7) The term `NDA' means a new drug application, as 
        defined under section 505(b) of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 355(b)).
            ``(8) The term `NDA holder' means--
                    ``(A) the party that received FDA approval to 
                market a drug product pursuant to an NDA;
                    ``(B) a party owning or controlling enforcement of 
                the patent listed in the Approved Drug Products With 
                Therapeutic Equivalence Evaluations (commonly known as 
                the `FDA Orange Book') in connection with the NDA; or
                    ``(C) the predecessors, subsidiaries, divisions, 
                groups, and affiliates controlled by, controlling, or 
                under common control with any of the entities described 
                in subclauses (i) and (ii) (such control to be presumed 
                by direct or indirect share ownership of 50 percent or 
                greater), as well as the licensees, licensors, 
                successors, and assigns of each of the entities.
            ``(9) The term `patent infringement' means infringement of 
        any patent or of any filed patent application, extension, 
        reissue, renewal, division, continuation, continuation in part, 
        reexamination, patent term restoration, patents of addition and 
        extensions thereof.
            ``(10) The term `patent infringement claim' means any 
        allegation made to an ANDA filer, whether or not included in a 
        complaint filed with a court of law, that its ANDA or ANDA 
        product may infringe any patent held by, or exclusively 
        licensed to, the NDA holder of the drug product.''.

SEC. 4. NOTICE AND CERTIFICATION OF AGREEMENTS.

    (a) Notice of All Agreements.--Section 1112(c)(2) of the Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 (21 
U.S.C. 3155 note) is amended by--
            (1) striking ``the Commission the'' and inserting ``the 
        Commission (1) the''; and
            (2) inserting before the period at the end the following: 
        ``; and (2) a description of the subject matter of any other 
        agreement the parties enter into within 30 days of an entering 
        into an agreement covered by subsection (a) or (b)''.
    (b) Certification of Agreements.--Section 1112 of such Act is 
amended by adding at the end the following:
    ``(d) Certification.--The Chief Executive Officer or the company 
official responsible for negotiating any agreement required to be filed 
under subsection (a), (b), or (c) shall execute and file with the 
Assistant Attorney General and the Commission a certification as 
follows: `I declare under penalty of perjury that the following is true 
and correct: The materials filed with the Federal Trade Commission and 
the Department of Justice under section 1112 of subtitle B of title XI 
of the Medicare Prescription Drug, Improvement, and Modernization Act 
of 2003, with respect to the agreement referenced in this 
certification: (1) represent the complete, final, and exclusive 
agreement between the parties; (2) include any ancillary agreements 
that are contingent upon, provide a contingent condition for, or are 
otherwise related to, the referenced agreement; and (3) include written 
descriptions of any oral agreements, representations, commitments, or 
promises between the parties that are responsive to subsection (a) or 
(b) of such section 1112 and have not been reduced to writing.'.''.

SEC. 5. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD.

    Section 505 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 
355(j)(5)(D)(i)(V)) is amended by inserting ``section 28 of the Clayton 
Act or'' after ``that the agreement has violated''.

SEC. 6. STUDY BY THE FEDERAL TRADE COMMISSION.

    (a) Requirement for a Study.--Not later than 180 days after the 
date of enactment of this Act and pursuant to its authority under 
section 6(a) of the Federal Trade Commission Act (15 U.S.C. 46(a)) and 
its jurisdiction to prevent unfair methods of competition, the Federal 
Trade Commission shall conduct a study regarding--
            (1) the prevalence of agreements in patent infringement 
        suits of the type described in section 28 of the Clayton Act, 
        as added by this Act, during the last 5 years;
            (2) the impact of such agreements on competition in the 
        pharmaceutical market; and
            (3) the prevalence in the pharmaceutical industry of other 
        anticompetitive agreements among competitors or other practices 
        that are contrary to the antitrust laws, and the impact of such 
        agreements or practices on competition in the pharmaceutical 
        market during the last 5 years.
    (b) Consultation.--In conducting the study required under this 
section, the Federal Trade Commission shall consult with the Antitrust 
Division of the Department of Justice regarding the Justice 
Department's findings and investigations regarding anticompetitive 
practices in the pharmaceutical market, including criminal antitrust 
investigations completed by the Justice Department with respect to 
practices or conduct in the pharmaceutical market.
    (c) Requirement for a Report.--Not later than 1 year after the date 
of enactment of this Act, the Federal Trade Commission shall submit a 
report to the Judiciary Committees of Senate and House of 
Representatives, and to the Department of Justice regarding the 
findings of the study conducted under subsection (a). This report shall 
contain the Federal Trade Commission's recommendation as to whether any 
amendment to the antitrust laws should be enacted to correct any 
substantial lessening of competition found during the study.
    (d) Federal Agency Consideration.--Upon receipt of the report 
required by subsection (c), the Attorney General or the Chairman of the 
Federal Trade Commission, as appropriate, shall consider whether any 
additional enforcement action is required to restore competition or 
prevent a substantial lessening of competition occurring as a result of 
the conduct or practices that were the subject of the study conducted 
under subsection (b).

SEC. 7. AUTHORIZATION OF APPROPRIATIONS.

    There are authorized to be appropriated to the Federal Trade 
Commission such sums as may be necessary to carry out the provisions of 
this Act.
Example Output:
Preserve Access to Affordable Generics Act - Amends the Clayton Act to make it unlawful for a person, in connection with the sale of a drug product, to be a party to any agreement resolving or settling a patent infringement claim in which: (1) an abbreviated new drug (generic) application filer receives anything of value; and (2) such filer agrees not to research, develop, manufacture, market, or sell the generic product for any period. Excludes a resolution or settlement that includes no more than the right to market the generic product prior to the expiration of the patent.

Amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to set forth additional filing requirements related to agreements between a brand name drug company and a generic drug applicant. Requires the Chief Executive Officer or the company official responsible for negotiating any agreement to file a certification that materials filed with respect to such agreements: (1) are complete, final, and exclusive; (2) include any ancillary agreements that are contingent upon, provide a contingent condition for, or are otherwise related to, the agreement; and (3) include written descriptions of any relevant oral agreements, representations, commitments, or promises between the parties that have not been reduced to writing.

Amends the Federal Food, Drug, and Cosmetic Act to provide that forfeiture of the 180-day exclusivity period for the marketing of a generic drug occurs if there is a final decision of the Federal Trade Commission (FTC) or the court that an agreement has violated this Act.

Requires the FTC to study the prevalence of anticompetitive agreements in the pharmaceutical industry and their impact. Requires the Attorney General or FTC to consider whether any additional enforcement action is necessary.

Authorizes appropriations.